[
  {
    "ts": null,
    "headline": "June's Top 10 High-Yield Stocks: Build A Path To A 10%+ Yield By 2035",
    "summary": "Discover the top 10 high-yield stocks for June 2025! Learn how to boost income with dividend growth, strong financials, and smart diversification...",
    "url": "https://finnhub.io/api/news?id=1a1690d0d6fa893c1191db6a53ce4c2ce65038e5023a9acbfc5ebed5211df28f",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748880000,
      "headline": "June's Top 10 High-Yield Stocks: Build A Path To A 10%+ Yield By 2035",
      "id": 134959783,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2156964801/image_2156964801.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover the top 10 high-yield stocks for June 2025! Learn how to boost income with dividend growth, strong financials, and smart diversification...",
      "url": "https://finnhub.io/api/news?id=1a1690d0d6fa893c1191db6a53ce4c2ce65038e5023a9acbfc5ebed5211df28f"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers Joins Pharma’s Hottest Horserace in $11.1B Deal With BioNTech",
    "summary": "Drugmakers hope a new class of cancer drugs could unseat Keytruda, the Merck immuno-oncology blockbuster.",
    "url": "https://finnhub.io/api/news?id=b7d942fd2d63c566448899c6372894371f9b18ddb03e77ca4d445cb347288570",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748878740,
      "headline": "Bristol Myers Joins Pharma’s Hottest Horserace in $11.1B Deal With BioNTech",
      "id": 134947665,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Drugmakers hope a new class of cancer drugs could unseat Keytruda, the Merck immuno-oncology blockbuster.",
      "url": "https://finnhub.io/api/news?id=b7d942fd2d63c566448899c6372894371f9b18ddb03e77ca4d445cb347288570"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference",
    "summary": "NEW YORK, June 02, 2025--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 8:00 a.m. Eastern Daylight Time.",
    "url": "https://finnhub.io/api/news?id=e3f04b0ac4f938a5ab727daf825a71c1d7154e4b7f4302deef79d769b0c3318f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748872800,
      "headline": "Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference",
      "id": 134939714,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "NEW YORK, June 02, 2025--Pfizer Inc. (NYSE: PFE) invites investors and the general public to listen to a webcast of a discussion with Albert Bourla, Chairman and Chief Executive Officer, at the Goldman Sachs 46th Annual Global Healthcare Conference on Monday, June 9, 2025 at 8:00 a.m. Eastern Daylight Time.",
      "url": "https://finnhub.io/api/news?id=e3f04b0ac4f938a5ab727daf825a71c1d7154e4b7f4302deef79d769b0c3318f"
    }
  },
  {
    "ts": null,
    "headline": "Bristol to Pay BioNTech Up to $11.1 Billion in Cancer Deal",
    "summary": "(Bloomberg) -- Bristol-Myers Squibb Co. will pay BioNTech SE as much as $11.1 billion to license a next-generation cancer drug, as competition intensifies in an area of oncology that seeks to harness the immune system to attack tumors.Most Read from BloombergBillionaire Steve Cohen Wants NY to Expand Taxpayer-Backed FerryWhere the Wild Children’s Museums AreNow With Colorful Blocks, Tirana’s Pyramid Represents a Changing AlbaniaThe Economic Benefits of Paying Workers to MoveNYC Congestion Toll B",
    "url": "https://finnhub.io/api/news?id=fac08862058836a0bd12c163076e9cee2ea5fb1809c3c3e4fe06c7034d5c8315",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748866028,
      "headline": "Bristol to Pay BioNTech Up to $11.1 Billion in Cancer Deal",
      "id": 134937241,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "(Bloomberg) -- Bristol-Myers Squibb Co. will pay BioNTech SE as much as $11.1 billion to license a next-generation cancer drug, as competition intensifies in an area of oncology that seeks to harness the immune system to attack tumors.Most Read from BloombergBillionaire Steve Cohen Wants NY to Expand Taxpayer-Backed FerryWhere the Wild Children’s Museums AreNow With Colorful Blocks, Tirana’s Pyramid Represents a Changing AlbaniaThe Economic Benefits of Paying Workers to MoveNYC Congestion Toll B",
      "url": "https://finnhub.io/api/news?id=fac08862058836a0bd12c163076e9cee2ea5fb1809c3c3e4fe06c7034d5c8315"
    }
  },
  {
    "ts": null,
    "headline": "Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential",
    "summary": "Discover why Altimmune (ALT) and Viking Therapeutics (VKTX) are top picks for high-risk investors. Click here to read my most recent analysis of ALT and VKTX.",
    "url": "https://finnhub.io/api/news?id=0ac383216799056c0449e2051217ef2970fabe0ca68a462d224c1e7cef48ed5d",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748861478,
      "headline": "Altimmune Vs. Viking Therapeutics: Evaluating Pipeline Maturity, And Takeover Potential",
      "id": 134941350,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/155007703/image_155007703.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover why Altimmune (ALT) and Viking Therapeutics (VKTX) are top picks for high-risk investors. Click here to read my most recent analysis of ALT and VKTX.",
      "url": "https://finnhub.io/api/news?id=0ac383216799056c0449e2051217ef2970fabe0ca68a462d224c1e7cef48ed5d"
    }
  },
  {
    "ts": null,
    "headline": "Put Cash To Work: 2 Magnificent Dividends I'm Betting On",
    "summary": "Discover why RTX & AbbVie are top picks for growth & income.",
    "url": "https://finnhub.io/api/news?id=055adbcc07b3c97a6108e18da5df5139ba8c3f57b9c90f63dc0ab0c36819f5d2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748858400,
      "headline": "Put Cash To Work: 2 Magnificent Dividends I'm Betting On",
      "id": 134939270,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1126636461/image_1126636461.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Discover why RTX & AbbVie are top picks for growth & income.",
      "url": "https://finnhub.io/api/news?id=055adbcc07b3c97a6108e18da5df5139ba8c3f57b9c90f63dc0ab0c36819f5d2"
    }
  },
  {
    "ts": null,
    "headline": "Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race",
    "summary": "Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race",
    "url": "https://finnhub.io/api/news?id=5ef7be33f4137c957a17b7a3964798438424975eb58ff3ed5ee5bf0d171506d7",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748853960,
      "headline": "Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race",
      "id": 134941480,
      "image": "",
      "related": "PFE",
      "source": "MarketWatch",
      "summary": "Bristol Myers makes $11 billion deal with BioNTech to join the cancer-drug race",
      "url": "https://finnhub.io/api/news?id=5ef7be33f4137c957a17b7a3964798438424975eb58ff3ed5ee5bf0d171506d7"
    }
  },
  {
    "ts": null,
    "headline": "Dividend Income Update: Q1 2025",
    "summary": "Dividend Income Update: Q1 2025",
    "url": "https://finnhub.io/api/news?id=1bc48b021ccc0e439220f7bfc982ca2890ecaa20fefd222526528d0e2534448e",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748843880,
      "headline": "Dividend Income Update: Q1 2025",
      "id": 134935601,
      "image": "",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "",
      "url": "https://finnhub.io/api/news?id=1bc48b021ccc0e439220f7bfc982ca2890ecaa20fefd222526528d0e2534448e"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer's BRAFTOVI Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer",
    "summary": "NEW YORK - Pfizer Inc. today announced statistically significant and clinically meaningful survival results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI in combination with cetuximab and...",
    "url": "https://finnhub.io/api/news?id=f9a60097a92ab149183fb07968152d6e8da0525169b8cb50c6dd950cf4231f26",
    "source": "Finnhub",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748842643,
      "headline": "Pfizer's BRAFTOVI Combination Regimen Cuts the Risk of Death in Half for Patients with BRAF V600E-Mutant Metastatic Colorectal Cancer",
      "id": 134935477,
      "image": "",
      "related": "PFE",
      "source": "Finnhub",
      "summary": "NEW YORK - Pfizer Inc. today announced statistically significant and clinically meaningful survival results from the Phase 3 BREAKWATER trial evaluating BRAFTOVI in combination with cetuximab and...",
      "url": "https://finnhub.io/api/news?id=f9a60097a92ab149183fb07968152d6e8da0525169b8cb50c6dd950cf4231f26"
    }
  },
  {
    "ts": null,
    "headline": "Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Pfizer (NYSE:PFE)",
    "summary": "Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Pfizer (NYSE:PFE) and its peers.",
    "url": "https://finnhub.io/api/news?id=885497d646f1a667b5936603e9f671929a8bac6de68e81c01d6b5e5da0aa4648",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1748835249,
      "headline": "Branded Pharmaceuticals Stocks Q1 Results: Benchmarking Pfizer (NYSE:PFE)",
      "id": 134937242,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Pfizer (NYSE:PFE) and its peers.",
      "url": "https://finnhub.io/api/news?id=885497d646f1a667b5936603e9f671929a8bac6de68e81c01d6b5e5da0aa4648"
    }
  }
]